Cases & Deals

Resonant Therapeutics enters into strategic alliance with Retrogenix to identify targets of anti-tumor antibodies

Clients Resonant Therapeutics, Inc.

Jones Day represented Resonant Therapeutics, Inc. in a strategic alliance with Retrogenix to identify the targets of Resonant antibodies directed against the tumor microenvironment. The collaboration exploits Resonant's proprietary IMPaCT tumor microenvironment models and data platform to discover novel, unappreciated targets and functionally active anti-tumor antibodies for difficult-to-treat tumors.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.